Dr. Elizabeth Goldspink, ND is a leader in preventive medicine and founder of Wellex, a science-based supplement company advancing hormonal, metabolic, and immune health for women. With over 16 years of clinical experience, she translates cutting-edge research into practical solutions that support energy, resilience, and long-term well-being.
A pioneer in women’s health innovation, Dr. Goldspink has formulated multiple category-defining products, including Papillex - Wellex’s flagship cervical health supplement, now undergoing a Health Canada–approved human clinical trial. Her work bridges rigorous science and accessible care, drawing from both published research (including peer-reviewed medical journals) and real-world outcomes in thousands of patients.
Dr. Goldspink earned her doctorate from the Canadian College of Naturopathic Medicine and completed training in Mind-Body Medicine at Harvard University under Dr. Herbert Benson, MD. She actively collaborates with physicians, researchers, and leading health institutions to expand the role of preventive and integrative care in modern medicine.
A sought-after voice in women’s health and longevity, Dr. Goldspink speaks widely on evidence-based approaches to hormonal balance, metabolic optimization, and cellular aging. She has been featured on Cityline, CP24 Breakfast TV, and leading podcasts, where she is recognized for her clarity, compassion, and clinical rigor.
ON DEMAND: Persistent HPV: What Every Naturopathic Doctor Should Know About Supporting Viral Clearance and Cervical Health
Day & Time TBD
Persistent HPV is often approached primarily as a viral infection requiring surveillance or procedural management. Yet viral persistence is rarely explained by the virus alone. It reflects a dynamic interaction between viral immune evasion and the host environment, including cell-mediated immunity, oxidative stress, nutritional status, smoking, sleep, psychological stress, and the cervicovaginal microenvironment. This session introduces a systems-based clinical framework that reframes persistent HPV as both a virus problem and an ecosystem problem.
Participants will move beyond asking, “What treats HPV?” and instead ask, “What may be preventing this patient from clearing it?” Current evidence will be translated into practical clinical reasoning across dietary patterns, targeted micronutrients and botanicals, lifestyle modification, immune resilience, and cervical and vaginal Health. The presentation will also address the frequently overlooked emotional and sexual-health burden of an HPV diagnosis, including stigma, fear, relationship distress, and chronic stress. Mind-body and trauma-informed strategies will be presented as components of whole-person care, with clear distinctions between established evidence, emerging evidence, and clinical experience.
Through a real patient journey involving persistent high-risk HPV and progressive cervical dysplasia, attendees will learn how to apply this framework without replacing indicated screening, surveillance, or gynecologic treatment. The session will also discuss formulation principles and an ongoing randomized controlled trial of a multi-ingredient nutritional intervention for persistent HPV. The central clinical shift is from searching for a single antiviral solution to strengthening the biological environment that supports immune-mediated clearance and long-term cervical resilience.
After the presentation, participants will be able to confidently:
Explain the natural history of HPV and distinguish transient infection from clinically consequential persistence.
Identify host and environmental factors associated with HPV persistence, including immune function, oxidative stress, nutritional status, smoking, sleep, psychological stress, and the cervicovaginal microbiome.
Critically evaluate the evidence for dietary strategies, targeted micronutrients, botanical medicines, and lifestyle interventions used to support cervical health and immune-mediated response to HPV.
Integrate stigma-sensitive, trauma-informed, and mind-body counseling into the care of patients living with persistent HPV.
Apply a systems-based framework to a patient case while maintaining appropriate screening, surveillance, referral, and shared decision-making.
ON DEMAND: The Cervicovaginal Microenvironment: Translating Emerging Science Into Clinical Practice
Day & Time TBD
For decades, recurrent cervicovaginal conditions have been managed primarily by identifying and suppressing a pathogen. Emerging science suggests that clinicians should pay equal attention to the ecosystem in which that pathogen exists. The vaginal microbiome, epithelial barrier, mucosal immunity, inflammation, hormonal status, pH, biofilms, sexual and behavioral factors, and environmental exposures interact to influence susceptibility, recurrence, and recovery. This session translates the rapidly evolving science of the cervicovaginal microenvironment into practical clinical care.
Participants will examine Lactobacillus-dominant community states, vaginal dysbiosis, local immune signaling, biofilms, estrogen-related changes, and the evidence linking cervicovaginal ecology with persistent HPV and recurrent bacterial vaginosis and vulvovaginal candidiasis. The presentation will critically evaluate current and emerging approaches, including conventional antimicrobial and antifungal therapy, probiotics, vaginal therapies and suppositories, nutritional and lifestyle factors, and strategies directed at recurrence. Particular attention will be given to strain specificity, route of administration, patient selection, safety, and the limits of current evidence so that clinicians can distinguish promising interventions from overstated claims. Case-based teaching will follow three contrasting patient journeys: persistent HPV with progressive cervical dysplasia, stress-associated recurrent HSV, and a five-year pattern of alternating bacterial vaginosis and vulvovaginal candidiasis. The targeted therapies differ across cases; the clinical framework remains consistent: identify the driver, support the host, restore the local environment, and preserve appropriate medical management.
The goal is not to create a sterile vagina, but to restore an ecosystem resilient enough to coexist with microbes while supporting long-term vaginal and cervical health.
After the presentation, participants will be able to confidently:
Explain how the vaginal microbiome, epithelial barrier, mucosal immunity, pH, hormones, inflammation, and biofilms interact within the cervicovaginal ecosystem.
Recognize clinical and behavioral factors that may contribute to vaginal dysbiosis, recurrent infection, and disruption of local resilience.
Critically appraise the evidence, limitations, and safety considerations for probiotics, vaginal therapies, suppositories, lifestyle interventions, and adjunctive integrative strategies.
Differentiate the clinical reasoning used for persistent HPV, recurrent HSV, bacterial vaginosis, and vulvovaginal candidiasis while identifying the shared ecosystem-based framework.
Develop individualized, evidence-informed management plans that complement appropriate diagnosis, conventional treatment, referral, and follow-up.

